Joao V. Alessi

Association of High Tumor Mutation Burden in Non–Small Cell Lung Cancers With Increased Immune Infiltration and Improved Clinical Outcomes of PD-L1 Blockade Across PD-L1 Expression Levels

Biagio Ricciuti, Xinan Wang, Joao V. Alessi et al. · JAMA Oncology · 2022 · 384 citations · Full text

Medicine, Cancer Biology, Oncology +17

Diminished Efficacy of Programmed Death-(Ligand)1 Inhibition in STK11- and KEAP1-Mutant Lung Adenocarcinoma Is Affected by KRAS Mutation Status

Biagio Ricciuti, Kathryn C. Arbour, Amir Vajdi et al. · Journal of Thoracic Oncology · 2021 · 367 citations · Full text

Medicine, Molecular Biology, Oncology +17

Comutations and KRASG12C Inhibitor Efficacy in Advanced NSCLC

Marcelo V. Negrão, Haniel A. Araújo, Giuseppe Lamberti et al. · Cancer Discovery · 2023 · 181 citations · Full text

Medicine, Molecular Genetics, Oncology +17

Early plasma circulating tumor DNA (ctDNA) changes predict response to first-line pembrolizumab-based therapy in non-small cell lung cancer (NSCLC)

Biagio Ricciuti, Greg Jones, Mariano Severgnini et al. · Journal for ImmunoTherapy of Cancer · 2021 · 159 citations · Full text

Life Sciences, Immunology, Oncology +17

SMARCA4 and Other SWItch/Sucrose NonFermentable Family Genomic Alterations in NSCLC: Clinicopathologic Characteristics and Outcomes to Immune Checkpoint Inhibition

Joao V. Alessi, Biagio Ricciuti, Liam F. Spurr et al. · Journal of Thoracic Oncology · 2021 · 149 citations

Medicine, Molecular Genetics, Oncology +14